This inventor holds 3 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignee: Pfizer Corporation. Active years: 2018-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018-2022
Title: Inventor Spotlight: Sriram Krishnaswami
Introduction
Sriram Krishnaswami is a notable inventor based in East Lyme, Connecticut. With a total of three patents to his name, he has significantly contributed to the field of pharmaceuticals, particularly in the development of innovative drug formulations.
Latest Patents
Sriram's latest patents focus on oral sustained release dosage forms of tofacitinib, a medication used to treat various inflammatory conditions. The formulations described in his inventions highlight desirable pharmacokinetic characteristics, making them valuable in therapeutic applications. Notably, this invention enhances the delivery and efficacy of tofacitinib through an improved release mechanism.
Career Highlights
Sriram is currently affiliated with Pfizer Corporation, a leading pharmaceutical company known for its dedication to research and innovation. His work at Pfizer allows him to collaborate with experts in the industry and contribute to cutting-edge medical solutions.
Collaborations
Throughout his career, Sriram has worked alongside notable colleagues such as Scott Max Herbig and Joseph Kushner. Collaborating with such experienced professionals has enriched his research and development endeavors, allowing for the cross-pollination of ideas and innovation.
Conclusion
Sriram Krishnaswami's contributions to pharmaceutical innovations are commendable, particularly in the area of sustained release formulations. His ongoing work at Pfizer Corporation and his collaborations with esteemed colleagues stand testament to his influence and importance in the field of medicine. As he continues to develop new solutions, Sriram remains a key player in advancing therapeutic options for patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
